Petr Vylet'al1, Kendrah Kidd1,2, Hannah C Ainsworth3, Drahomíra Springer4, Alena Vrbacká1, Anna Přistoupilová1, Rebecca P Hughey5, Seth L Alper6,7, Niall Lennon6, Steven Harrison6, Maegan Harden6, Victoria Robins2, Abbigail Taylor2, Lauren Martin2, Katrice Howard2, Ibrahim Bitar8, Carl D Langefeld3, Veronika Barešová1, Hana Hartmannová1, Kateřina Hodaňová1, Tomáš Zima4, Martina Živná1, Stanislav Kmoch1,2, Anthony J Bleyer1,2. 1. Department of Paediatrics and Inherited Metabolic Disorders, Research Unit of Rare Diseases, First Faculty of Medicine, Charles University, Prague, Czechia. 2. Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 3. Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 4. Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and the First Faculty of Medicine of Charles University, Prague, Czechia. 5. Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 6. The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. 7. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. 8. Biomedical Center and Institute of Microbiology, Faculty of Medicine in Pilsen of Charles University, Pilsen, Czechia.
Abstract
INTRODUCTION: Patients with ADTKD-MUC1 have one allele producing normal mucin-1 (MUC1) and one allele producing mutant MUC1, which remains intracellular. We hypothesized that ADTKD-MUC1 patients, who have only 1 secretory-competent wild-type MUC1 allele, should exhibit decreased plasma mucin-1 (MUC1) levels. To test this hypothesis, we repurposed the serum CA15-3 assay used to measure MUC1 in breast cancer to measure plasma MUC1 levels in ADTKD-MUC1. METHODS: This cross-sectional study analyzed CA15-3 levels in a reference population of 6,850 individuals, in 85 individuals with ADTKD-MUC1, and in a control population including 135 individuals with ADTKD-UMOD and 114 healthy individuals. RESULTS: Plasma CA15-3 levels (mean ± standard deviation) were 8.6 ± 4.3 U/mL in individuals with ADTKD-MUC1 and 14.6 ± 5.6 U/mL in controls (p < 0.001). While there was a significant difference in mean CA15-3 levels, there was substantial overlap between the 2 groups. Plasma CA15-3 levels were <5 U/mL in 22% of ADTKD-MUC1 patients, in 0/249 controls, and in 1% of the reference population. Plasma CA15-3 levels were >20 U/mL in 1/85 ADTKD-MUC1 patients, in 18% of control individuals, and in 25% of the reference population. Segregation of plasma CA15-3 levels by the rs4072037 genotype did not significantly improve differentiation between affected and unaffected individuals. CA15-3 levels were minimally affected by gender and estimated glomerular filtration rate. DISCUSSION/ CONCLUSIONS: Plasma CA15-3 levels in ADTKD-MUC1 patients are approximately 40% lower than levels in healthy individuals, though there is significant overlap between groups. Further investigations need to be performed to see if plasma CA15-3 levels would be useful in diagnosis, prognosis, or assessing response to new therapies in this disorder.
INTRODUCTION: Patients with ADTKD-MUC1 have one allele producing normal mucin-1 (MUC1) and one allele producing mutant MUC1, which remains intracellular. We hypothesized that ADTKD-MUC1 patients, who have only 1 secretory-competent wild-type MUC1 allele, should exhibit decreased plasma mucin-1 (MUC1) levels. To test this hypothesis, we repurposed the serum CA15-3 assay used to measure MUC1 in breast cancer to measure plasma MUC1 levels in ADTKD-MUC1. METHODS: This cross-sectional study analyzed CA15-3 levels in a reference population of 6,850 individuals, in 85 individuals with ADTKD-MUC1, and in a control population including 135 individuals with ADTKD-UMOD and 114 healthy individuals. RESULTS: Plasma CA15-3 levels (mean ± standard deviation) were 8.6 ± 4.3 U/mL in individuals with ADTKD-MUC1 and 14.6 ± 5.6 U/mL in controls (p < 0.001). While there was a significant difference in mean CA15-3 levels, there was substantial overlap between the 2 groups. Plasma CA15-3 levels were <5 U/mL in 22% of ADTKD-MUC1 patients, in 0/249 controls, and in 1% of the reference population. Plasma CA15-3 levels were >20 U/mL in 1/85 ADTKD-MUC1 patients, in 18% of control individuals, and in 25% of the reference population. Segregation of plasma CA15-3 levels by the rs4072037 genotype did not significantly improve differentiation between affected and unaffected individuals. CA15-3 levels were minimally affected by gender and estimated glomerular filtration rate. DISCUSSION/ CONCLUSIONS: Plasma CA15-3 levels in ADTKD-MUC1 patients are approximately 40% lower than levels in healthy individuals, though there is significant overlap between groups. Further investigations need to be performed to see if plasma CA15-3 levels would be useful in diagnosis, prognosis, or assessing response to new therapies in this disorder.
Authors: Brendan Blumenstiel; Matthew DeFelice; Ozge Birsoy; Anthony J Bleyer; Stanislav Kmoch; Todd A Carter; Andreas Gnirke; Kendrah Kidd; Heidi L Rehm; Lucienne Ronco; Eric S Lander; Stacey Gabriel; Niall J Lennon Journal: J Mol Diagn Date: 2016-05-05 Impact factor: 5.568
Authors: Lesley A Stevens; Christopher H Schmid; Tom Greene; Yaping Lucy Zhang; Gerald J Beck; Marc Froissart; Lee L Hamm; Julia B Lewis; Michael Mauer; Gerjan J Navis; Michael W Steffes; Paul W Eggers; Josef Coresh; Andrew S Levey Journal: Am J Kidney Dis Date: 2010-06-16 Impact factor: 8.860
Authors: Eric Olinger; Patrick Hofmann; Kendrah Kidd; Inès Dufour; Hendrica Belge; Céline Schaeffer; Anne Kipp; Olivier Bonny; Constantinos Deltas; Nathalie Demoulin; Thomas Fehr; Daniel G Fuster; Daniel P Gale; Eric Goffin; Kateřina Hodaňová; Uyen Huynh-Do; Andreas Kistler; Johann Morelle; Gregory Papagregoriou; Yves Pirson; Richard Sandford; John A Sayer; Roser Torra; Christina Venzin; Reto Venzin; Bruno Vogt; Martina Živná; Anna Greka; Karin Dahan; Luca Rampoldi; Stanislav Kmoch; Anthony J Bleyer; Olivier Devuyst Journal: Kidney Int Date: 2020-05-22 Impact factor: 10.612
Authors: Andrea Wenzel; Janine Altmueller; Arif B Ekici; Bernt Popp; Kurt Stueber; Holger Thiele; Alois Pannes; Simon Staubach; Eduardo Salido; Peter Nuernberg; Richard Reinhardt; André Reis; Patrick Rump; Franz-Georg Hanisch; Matthias T F Wolf; Michael Wiesener; Bruno Huettel; Bodo B Beck Journal: Sci Rep Date: 2018-03-08 Impact factor: 4.379
Authors: Andrew Kirby; Andreas Gnirke; David B Jaffe; Veronika Barešová; Nathalie Pochet; Brendan Blumenstiel; Chun Ye; Daniel Aird; Christine Stevens; James T Robinson; Moran N Cabili; Irit Gat-Viks; Edward Kelliher; Riza Daza; Matthew DeFelice; Helena Hůlková; Jana Sovová; Petr Vylet'al; Corinne Antignac; Mitchell Guttman; Robert E Handsaker; Danielle Perrin; Scott Steelman; Snaevar Sigurdsson; Steven J Scheinman; Carrie Sougnez; Kristian Cibulskis; Melissa Parkin; Todd Green; Elizabeth Rossin; Michael C Zody; Ramnik J Xavier; Martin R Pollak; Seth L Alper; Kerstin Lindblad-Toh; Stacey Gabriel; P Suzanne Hart; Aviv Regev; Chad Nusbaum; Stanislav Kmoch; Anthony J Bleyer; Eric S Lander; Mark J Daly Journal: Nat Genet Date: 2013-02-10 Impact factor: 38.330